Overview

An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Status:
Enrolling by invitation
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304
Phase:
Phase 2
Details
Lead Sponsor:
TG Therapeutics, Inc.